Spike S1 (B.1.351, Beta Variant), Avi-His-Tag (SARS-CoV-2) Recombinant
Catalog #
100992
$320
*
●
●
Purchase
Description
Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351, also known as variant Beta originally identified in South Africa, and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, and D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein was affinity purified.
●
Synonyms
501Y.V2, South Africa mutation, South African variant, beta variant
●
Product Data Gallery
4-20% SDS-Page Coomassie Staining
Product Info
Storage and Usage
Citations
Species
SARS-CoV-2
Construct
Spike S1 (B.1.351 Variant) (16-685-Avi-His) (SARS-CoV-2)
Mutation
L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G
Host Species/Expression System
HEK293
Purity
≥90%
Supplied As
Aqueous buffer solution.
Formulation
8mM phosphate, pH 7.4, 110mM NaCl, 2.2mM KCl, and 20% glycerol.
MW
78 kDa + glycans
Amino Acids
16-685
Glycosylation
This protein runs at higher MW by SDS-PAGE due to glycosylation.
Genbank #
MN908947
UniProt #
P0DTC2
Background
SARS-COV-2 Variant B.1.351 was first identified in the fall of 2020 in the Republic of South Africa. This variant, also known as 501Y.V2, has many mutations which may lead to higher transmissibility and infectivity. In particular, the B.1.351 variant contains three mutations within the RBD region of the Spike S1 protein: K417N, E484K, and N501Y. Investigating the effect of mutations on viral replication and pathogenesis will be critical for developing effective strategies for vaccines and antibody therapies against COVID-19.
Powered by Bioz
6405 Mira Mesa Blvd. Suite 100
San Diego, CA 92121
858-202-1401
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.